This article was originally published in The Tan Sheet
Relief of travelers' diarrhea is included as an indication for bismuth subsalicylate products in the final monograph for OTC antidiarrheal drug products, effective June 11, FDA reports in the May 12 Federal Register. The condition is described as "a subset of diarrhea occurring in travelers that is most commonly caused by an infectious agent." The approval responds to requests made in response to the 1986 TFM on antidiarrheals (1"The Tan Sheet" April 21, 2003, p. 4). Web materials for Procter & Gamble's Pepto-Bismol already provide information on the condition...
You may also be interested in...
Relief of travelers' diarrhea would be included as an indication for bismuth subsalicylate products in the OTC antidiarrheal drug final monograph under a proposed rule published in the 1April 17 Federal Register
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.